Menu

Theranos CEO Banned from Running Labs for Two Years

Federal regulators also revoked a certificate for the company’s Newark, California lab.

Jul 8, 2016
Tanya Lewis

Elizabeth HolmesWIKIMEDIA, GLENN FAWCETTA government health regulator has banned Elizabeth Holmes, founder and CEO of the embattled blood testing startup Theranos, from operating a lab for at least two years, the company announced yesterday (July 8). The Centers for Medicare & Medicaid Services (CMS) also yanked the certificate for its Newark, California lab, imposed an unspecified fine, and suspended approval of Medicare and Medicaid payments for lab services, according to the statement.

“We accept full responsibility for the issues at our laboratory in Newark, California, and have already worked to undertake comprehensive remedial actions,” Holmes said in the statement. “While we are disappointed by CMS’ decision, we take these matters very seriously and are committed to fully resolving all outstanding issues with CMS and to demonstrating our dedication to the highest standards of quality and compliance.”

The Newark lab’s revocation takes effect in two months’ time, but Theranos said it would not conduct any patient testing there “until further notice.” In the meantime, the facility will be shut down and rebuilt “from the ground up,” and the company will hire new leadership and personnel, Homes said in the statement. The company said it will continue to serve customers at its Arizona lab.

Theranos, which was founded by Holmes in 2003 and was previously valued at $9 billion, is now worth about $800 million, according to Ars Technica. Federal officials launched a criminal probe into the company following media reports questioning the accuracy of its claims. Walgreens recently ended its partnership with the company. 

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!